תבנית:תרופה/לוסרדקס 50 - Losardex 50: הבדלים בין גרסאות

|התוויה={{{התוויה|<div style="direction:ltr;">Hypertension: Losardex is indicated for the treatment of hypertension. Heart failure: Losardex is indicated for the treatment of heart failure (NYHA II and III) usually in addition to diuretics and/or digitalis if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losardex is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Losardex on the primary deposite endpoint was largely driven by reduction in the risk of stroke.</div>}}}

|התוויה={{{התוויה|<div style="direction:ltr;">Hypertension: Losardex is indicated for the treatment of hypertension. Heart failure: Losardex is indicated for the treatment of heart failure (NYHA II and III) usually in addition to diuretics and/or digitalis if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losardex is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Losardex on the primary deposite endpoint was largely driven by reduction in the risk of stroke.</div>}}}

|שם יצרן={{{שם יצרן|[[יצרן::DEXCEL LTD]]}}}

|שם יצרן={{{שם יצרן|[[יצרן::DEXCEL LTD]]}}}

|שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::DEXCEL PHARMA TECHNOLOGIES LTD]]}}}

|שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::DEXCEL PHARMA TECHNOLOGIES LTD]]}}}

|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::03/2013]]}}}

|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::03/2013]]}}}

|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Losardex 50|לוסרדקס 50}}}}}

|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Losardex 50|לוסרדקס 50}}}}}

|עלון לרופא={{{עלון לרופא|}}}

|עלון לרופא={{{עלון לרופא|}}}

|עלון לצרכן={{{עלון לצרכן|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Losardex_pt_1377581912066.pdf עלון לצרכן]}}}

|עלון לצרכן={{{עלון לצרכן|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Losardex_pt_1377581912066.pdf עלון לצרכן]}}}

|החמרות לעלון={{{החמרות לעלון|}}}

|החמרות לעלון={{{החמרות לעלון|}}}

|שיווק הופסק={{{שיווק הופסק|לא}}}

|שיווק הופסק={{{שיווק הופסק|לא}}}

|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}}

|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}}

}}

}}

<noinclude>{{תרופה/תיעוד}}</noinclude>

<noinclude>{{תרופה/תיעוד}}</noinclude>